Cartesian Therapeutics Inc (RNAC) - News Archive

A New Dawn for Autoimmune Diseases: Cartesian Therapeutics Descartes-08 Shows Promising Results in SLE and Myasthenia GravisIn a landscape where autoimmune diseases such as systemic lupus erythematosus (SLE) and myasthe...

Cartesian Therapeutics Solidifies Talent Strategy with Inducement Grants Amid Steady Revenue GrowthFREDERICK, Md. May 2, 2025 Cartesian Therapeutics, Inc. (NASDAQ: RNAC), a prominent player in the biotechnology sector n...

In a strategic move to attract top-tier talent, Cartesian Therapeutics, Inc. (NASDAQ: RNAC), a pioneering biotechnology company focused on mRNA cell therapies for autoimmune diseases, has recently announced the granting...

Cartesian Therapeutics Reinforces Talent Acquisition with Inducement Grants Amid Market DynamicsFREDERICK, Md. February 6, 2025 Cartesian Therapeutics, Inc. (NASDAQ: RNAC), a prominent player in the clinical-stage biote...

Frederick, Md. January 07, 2025 In a continuing demonstration of confidence in its strategic direction, Cartesian Therapeutics, Inc. (NASDAQ: RNAC), a trailblazer in the development of mRNA cell therapies for autoimmune...

In an exciting development for the field of immunotherapy, Cartesian Therapeutics is set to present updated data from its Phase 2b clinical trial of Descartes-08, a novel therapeutic approach for the treatment of Myasth...

Cartesian Therapeutics Announces Strategic Employment Inducement Grants to Accelerate Growth and Talent AcquisitionIn the rapidly evolving landscape of biotechnology, companies must not only innovate but also attract an...

In the realm of biotechnology and therapeutics, innovation continually shapes the landscape of treatment options available for complex and often debilitating conditions. Cartesian Therapeutics is making remarkable strid...

In a strategic move reflecting its commitment to expansion and innovation, Cartesian Therapeutics, Inc. (NASDAQ: RNAC), a clinical-stage biotechnology company at the forefront of developing mRNA cell therapies for autoi...

Cartesian Therapeutics, a pioneering cellular therapeutics company, has made significant strides in the field of pediatric medicine. Recently, the company announced that it has received the U.S. Food and Drug Administra...

Cartesian Therapeutics Grants New Employee Inducement Award: A Sign of Growth and Investment in the FutureAs of the writing of this article, Cartesian Therapeutics Inc s share price stands at $14.04. While the stock has...

In a significant leap forward in the field of cancer therapy, Cartesian Therapeutics, a pioneering biotechnology firm specializing in the development of next-generation mRNA-based cell therapies, has announced that the...

Gaithersburg-based biotechnology company, Cartesian Therapeutics Inc. (NASDAQ: RNAC), continues its progress in the development of mRNA cell therapies for autoimmune diseases. In a recent press release, the company anno...

Cartesian Therapeutics Inc has had a tumultuous month in the market, with its shares trailing the overall market performance and lacking significant gains year to date. Several events have impacted the company s perform...

In a recent press release, Cartesian Therapeutics, a clinical-stage biotechnology company, revealed its decision to grant inducement awards to new employees. These awards include options to purchase company shares and a...

In a recent announcement, Cartesian Therapeutics, a clinical-stage biotechnology company focusing on mRNA cell therapy for autoimmune diseases, revealed that it has entered into a securities purchase agreement for priva...

In a major breakthrough, Cartesian Therapeutics has recently announced positive topline results from their Phase 2b trial of Descartes-08, a promising gene therapy for patients suffering from Myasthenia Gravis (MG). The...

GAITHERSBURG, Md., June 06, 2024 - Cartesian Therapeutics, Inc. (NASDAQ: RNAC), a leading clinical-stage biotechnology company specializing in mRNA cell therapies for autoimmune diseases, made an exciting announcement t...

Cartesian Therapeutics Implements Strategic Changes and Grants New Inducement AwardCartesian Therapeutics, a clinical-stage biotechnology company specializing in mRNA cell therapies for autoimmune diseases, has recently...

Cartesian Therapeutics, a clinical-stage biotechnology company specializing in mRNA cell therapies for autoimmune diseases, recently announced that it has granted an inducement award to a new employee. The award include...